Bluebird Bio Competitors and Similar CompaniesClear all
Bluebird Bio's competitors and similar companies include Tanvex BioPharma, G1 Therapeutics, Genprex and Bellicum Pharmaceuticals.
 Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  Bellicum Pharmaceuticals Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies. | |||
Founding Date | Founding Date 1992 | Founding Date 2013 | Founding Date 2008 | Founding Date 2009 | Founding Date 2004 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Somerville, US HQ | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Durham, US HQ | Locations West Lake Hills, US HQ Austin, US | Locations Houston, US HQ Houston, US Houston, US South San Francisco, US |
Employees | Employees 32338% decrease | Employees 13827% decrease | Employees 17015% increase | Employees 2865% increase | Employees 1386% increase |
Valuation ($) | Valuation ($) 95.4 m | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) 6.3 m | Valuation ($) 778.3 k |
Financial | |||||
Revenue (est.) | Revenue (est.) $83.8m (FY, 2024) | Revenue (est.) NT$34.7m (FY, 2024) | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) $1.5m (FY, 2022) |
Cost of goods | Cost of goods $89.4m (FY, 2024) | Cost of goods NT$26.4m (FY, 2024) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit ($5.6m) (FY, 2024) | Gross profit NT$8.7m (FY, 2024) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($240.7m) (FY, 2024) | Net income (NT$1.4b) (FY, 2024) | Net income ($48m) (FY, 2023) | Net income ($21.1m) (FY, 2024) | Net income ($25m) (FY, 2022) |
Operating ⚠ | |||||
Patents and Patent Applications | Patents and Patent Applications 1.2 k (FY, 2020) | Patents and Patent Applications N/A | Patents and Patent Applications 350 (FY, 2020) | Patents and Patent Applications N/A | Patents and Patent Applications N/A |
Funding | |||||
Total funding raised | Total funding raised $ 409m | Total funding raised $ 346.9m | Total funding raised $ 289.6m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Tanvex BioPharma
HQ
Taipei, TW
Employees
138↓ 27% decrease
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View companyG1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View company
Genprex
HQ
West Lake Hills, US
Employees
28
Genprex is a gene therapy company developing treatments for cancer and diabetes.
View companyBellicum Pharmaceuticals
HQ
Houston, US
Employees
13
Bellicum Pharmaceuticals is a biopharmaceutical company focused on discovering and developing cellular immunotherapies.
View company